Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device


; pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to or affecting Medicare, Medicaid and healthcare reform, pharmaceutical pricing and reimbursement, access to the company’s products, international reference pricing, including most-favored-nation drug pricing, and other pricing related initiatives and policy efforts; the impact of tariffs and other trade restrictions or domestic sourcing requirements; expanded brand and class competition in the markets in which the company operates; the failure of any supplier to provide substances, materials, or services as agreed, or otherwise meet their obligations to the company; the increased cost of supply, manufacturing, packaging, and operations; difficulties developing and sustaining relationships with commercial counterparties, including Sebela Pharmaceuticals; the impact of higher selling and promotional costs; efficacy, safety or other quality concerns with respect to the company’s marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, labeling changes or declining sales; future actions of third parties, including significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and forgoing healthcare insurance coverage; the failure by the company or its third party collaborators and/or their suppliers to fulfill their or their regulatory or quality obligations; and volatility of commodity prices, fuel, and shipping rates that impact the costs and/or ability to supply the company’s products. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the SEC, including the company’s most recent Annual Report on Form 10-K and subsequent SEC filings (including amendments thereto), available at the SEC’s Internet site (



Source link

  • Related Posts

    We Scoured Sales to Find the Best Skechers Post-Prime Day Deals

    Amazon Prime Day has ended, but Prime members can still get discounts on beauty and wellness essentials, home and cleaning items and editor-favorite sneakers. If the latter is what you’re…

    Nissan Cuts Costs on Mexico-Made Cars to Mitigate 25% Tariffs

    (Bloomberg) — Nissan Motor Co. is working to cut costs on Mexico-made models to blunt the impact of tariffs that have rendered its vehicles tougher to sell in the US,…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Canada Day a moment of pride, patriotism and melanchony in Alberta

    Canada Day a moment of pride, patriotism and melanchony in Alberta

    How the Liberty beat the Aces for the Commissioner’s Cup title

    How the Liberty beat the Aces for the Commissioner’s Cup title

    Catholic Group Consecrates 4 Bishops, Risking Break With Vatican

    WATCH: Couple speaks out on wedding world-record attempts

    WATCH:  Couple speaks out on wedding world-record attempts

    We Scoured Sales to Find the Best Skechers Post-Prime Day Deals

    We Scoured Sales to Find the Best Skechers Post-Prime Day Deals

    SpaceX may donate stock to Trump’s savings accounts for kids, report says

    SpaceX may donate stock to Trump’s savings accounts for kids, report says